<DOC>
	<DOCNO>NCT00626106</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , phase 2 study . Subjects include postmenopausal woman confirm HR-positive , locally advanced metastatic breast cancer , disease progression within 12 month complete prior adjuvant endocrine therapy first prior endocrine therapy metastatic disease .</brief_summary>
	<brief_title>QUILT-2.015 : A Study AMG 479 With Exemestane Fulvestrant Postmenopausal Women With Hormone Receptor Positive Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically confirm carcinoma breast locally advance metastatic disease Confirmation hormone receptor ( HR ) positive disease status Amenable receive endocrine therapy Disease progression receive prior endocrine therapy locally advance metastatic breast cancer Postmenopausal woman â‰¥ 18 year old HRunknown HRnegative disease Not amenable endocrine therapy Central nervous system metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>postmenopausal</keyword>
	<keyword>hormone receptor positive</keyword>
	<keyword>locally advanced</keyword>
	<keyword>metastatic</keyword>
</DOC>